Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety/tolerability of Grass MATA MPL a randomized, placebo-controlled, double-blind study

Next Previous
Trial Profile

Efficacy and safety/tolerability of Grass MATA MPL a randomized, placebo-controlled, double-blind study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Acronyms RESONATE
  • Sponsors Allergy Therapeutics

Most Recent Events

  • 29 Apr 2011 Results published in Allergy and Asthma Proceedings.
  • 22 Mar 2011 Subgroup analysis results presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 07 Jun 2010 Results have been presented at the XXIV Congress of The European Academy of Allergy and Clinical Immunology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top